FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039183257> ?p ?o ?g. }

• W3039183257 abstract "Background: Apatinib is a powerful inhibitor of vascular endothelial growth factor receptor-2. This study was to investigate whether apatinib could improve the efficacy of transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC). Methods: Between June 2015 and September 2018, 357 patients with HCC at Barcelona Clinic Liver Cancer stage C who received the treatment of TACE combining with apatinib (TACE-apatinib) or TACE-alone were included. Propensity score matching (PSM) analysis was used to reduce the patient selection bias. Results: Ninety pairs of patients were chosen after PSM analysis. The disease control rates of tumor and a-fetoprotein response in the TACE-apatinib group were significantly higher than that of the TACE-alone group before and after PSM analysis (P<0.05). Before PSM analysis, the median time of progression (TTP) and overall survival (OS) in the TACE-apatinib group was significantly greater than that of the TACE-alone group (TTP: 9.0 months versus 3.0 months, P<0.001; OS: 14.0 months versus 7.0 months, P<0.001 ). After PSM analysis, the median TTP and OS in the TACE-apatinib group was also significantly greater than that of the TACE-alone group (TTP: 7.0 months versus 3.0 months, P<0.001; OS: 13.0 months versus 8.0 months, P<0.001); the uni- and multivariate analysis revealed that TACE-apatinib was a protective factor for OS. Fourteen patients emerged with grade 3 apatinib-related adverse events. Conclusion: The efficacy of TACE-apatinib for patients with advanced HCC was inspiring, and the side effects of apatinib were tolerable." @default.
• W3039183257 created "2020-07-10" @default.
• W3039183257 creator A5005040479 @default.
• W3039183257 creator A5005397465 @default.
• W3039183257 creator A5026393563 @default.
• W3039183257 creator A5027041701 @default.
• W3039183257 creator A5027271655 @default.
• W3039183257 creator A5030938471 @default.
• W3039183257 creator A5037195175 @default.
• W3039183257 creator A5040973067 @default.
• W3039183257 creator A5055895731 @default.
• W3039183257 creator A5075012859 @default.
• W3039183257 date "2020-07-07" @default.
• W3039183257 modified "2023-10-01" @default.
• W3039183257 title "Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis" @default.
• W3039183257 cites W1601002325 @default.
• W3039183257 cites W1922647212 @default.
• W3039183257 cites W1971837077 @default.
• W3039183257 cites W1981186476 @default.
• W3039183257 cites W1994193851 @default.
• W3039183257 cites W1996703005 @default.
• W3039183257 cites W1997533142 @default.
• W3039183257 cites W2037135054 @default.
• W3039183257 cites W2037678476 @default.
• W3039183257 cites W2057378223 @default.
• W3039183257 cites W2079586464 @default.
• W3039183257 cites W2088624675 @default.
• W3039183257 cites W2113935263 @default.
• W3039183257 cites W2132006978 @default.
• W3039183257 cites W2136512959 @default.
• W3039183257 cites W2142123446 @default.
• W3039183257 cites W2145092426 @default.
• W3039183257 cites W2162741760 @default.
• W3039183257 cites W2163486683 @default.
• W3039183257 cites W2168997800 @default.
• W3039183257 cites W2178658282 @default.
• W3039183257 cites W2277004004 @default.
• W3039183257 cites W2293170306 @default.
• W3039183257 cites W2591717879 @default.
• W3039183257 cites W2618360530 @default.
• W3039183257 cites W2661307008 @default.
• W3039183257 cites W2742577150 @default.
• W3039183257 cites W2886354380 @default.
• W3039183257 cites W2896972634 @default.
• W3039183257 cites W2900798662 @default.
• W3039183257 cites W2953976355 @default.
• W3039183257 cites W2961326079 @default.
• W3039183257 cites W4245784696 @default.
• W3039183257 cites W785602768 @default.
• W3039183257 doi "https://doi.org/10.3389/fonc.2020.00970" @default.
• W3039183257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7358575" @default.
• W3039183257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32733791" @default.
• W3039183257 hasPublicationYear "2020" @default.
• W3039183257 type Work @default.
• W3039183257 sameAs 3039183257 @default.
• W3039183257 citedByCount "33" @default.
• W3039183257 countsByYear W30391832572020 @default.
• W3039183257 countsByYear W30391832572021 @default.
• W3039183257 countsByYear W30391832572022 @default.
• W3039183257 countsByYear W30391832572023 @default.
• W3039183257 crossrefType "journal-article" @default.
• W3039183257 hasAuthorship W3039183257A5005040479 @default.
• W3039183257 hasAuthorship W3039183257A5005397465 @default.
• W3039183257 hasAuthorship W3039183257A5026393563 @default.
• W3039183257 hasAuthorship W3039183257A5027041701 @default.
• W3039183257 hasAuthorship W3039183257A5027271655 @default.
• W3039183257 hasAuthorship W3039183257A5030938471 @default.
• W3039183257 hasAuthorship W3039183257A5037195175 @default.
• W3039183257 hasAuthorship W3039183257A5040973067 @default.
• W3039183257 hasAuthorship W3039183257A5055895731 @default.
• W3039183257 hasAuthorship W3039183257A5075012859 @default.
• W3039183257 hasBestOaLocation W30391832571 @default.
• W3039183257 hasConcept C126322002 @default.
• W3039183257 hasConcept C143998085 @default.
• W3039183257 hasConcept C167734588 @default.
• W3039183257 hasConcept C17923572 @default.
• W3039183257 hasConcept C197934379 @default.
• W3039183257 hasConcept C2777025900 @default.
• W3039183257 hasConcept C2778019345 @default.
• W3039183257 hasConcept C2780668389 @default.
• W3039183257 hasConcept C3019894029 @default.
• W3039183257 hasConcept C71924100 @default.
• W3039183257 hasConcept C90924648 @default.
• W3039183257 hasConceptScore W3039183257C126322002 @default.
• W3039183257 hasConceptScore W3039183257C143998085 @default.
• W3039183257 hasConceptScore W3039183257C167734588 @default.
• W3039183257 hasConceptScore W3039183257C17923572 @default.
• W3039183257 hasConceptScore W3039183257C197934379 @default.
• W3039183257 hasConceptScore W3039183257C2777025900 @default.
• W3039183257 hasConceptScore W3039183257C2778019345 @default.
• W3039183257 hasConceptScore W3039183257C2780668389 @default.
• W3039183257 hasConceptScore W3039183257C3019894029 @default.
• W3039183257 hasConceptScore W3039183257C71924100 @default.
• W3039183257 hasConceptScore W3039183257C90924648 @default.
• W3039183257 hasFunder F4320321001 @default.
• W3039183257 hasFunder F4320322186 @default.
• W3039183257 hasLocation W30391832571 @default.
• W3039183257 hasLocation W30391832572 @default.
• W3039183257 hasLocation W30391832573 @default.
• W3039183257 hasOpenAccess W3039183257 @default.

• next